Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.
Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-induced lung toxicity after receiving high-dose cyclophosphamide, at a time-frame much shorter than would have been predicted with cyclophosphamide alone. The potential for enhanced lung toxicity secondary to combination of amiodarone and cyclophosphamide is discussed.
Bhagat
R
R
Division of Pulmonary and Critical Care Medicine, Duke University Adult Bone Marrow Transplant Program, Duke University Medical Center, Durham, NC 27710, USA.
Sporn
T A
TA
Long
G D
GD
Folz
R J
RJ
D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004357:Drug Synergism; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011859:Radiography
D003520:Cyclophosphamide; D000638:Amiodarone